Yes—in a 56-day study, enlicitide lowered LDL Cholesterol by 64.6%, more than the other add-on pills tested. For this community, another result matters: Apolipoprotein B (ApoB) also fell more with enlicitide. The source does not give the exact percentage drop for this marker. The 64.6% drop applies to cholesterol, not this marker. The study tested enlicitide, a new cholesterol-lowering pill, in 301 adults. Everyone was already taking Statins, medicines that lower cholesterol. Their average age was 64.4 years, and 37% were women. They had either experienced a major heart or blood vessel problem or faced an increased risk of one. People were assigned by chance to one of four daily treatments. These were enlicitide, Bempedoic Acid, Ezetimibe, or the last two medicines together. All were added to their existing treatment. Of the 301 people, 298 finished the study. At day 56, average LDL Cholesterol fell 64.6% with enlicitide. Drops were 6.3% with Bempedoic Acid and 27.8% with Ezetimibe. Taking those two together produced a 36.5% drop. Non-HDL Cholesterol also fell more with enlicitide. Rates of side effects, and stopping treatment because of them, were similar across groups. These results show larger short-term changes in bloodwork, not proof of fewer heart attacks. For BioSocial members, they also highlight why each marker deserves its own record. Uploading before-and-after bloodwork, treatment details, and test dates can make community comparisons more useful. Group averages offer context, but they do not predict anyone’s exact response. What changes have you seen in your own bloodwork after adding a cholesterol medicine?